BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BudMaps - ECPv6.0.13.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://budmaps.com.br
X-WR-CALDESC:Eventos para BudMaps
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Sao_Paulo
BEGIN:STANDARD
TZOFFSETFROM:-0200
TZOFFSETTO:-0300
TZNAME:-03
DTSTART:20170219T020000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0300
TZOFFSETTO:-0200
TZNAME:-02
DTSTART:20171015T030000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0200
TZOFFSETTO:-0300
TZNAME:-03
DTSTART:20180218T020000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0300
TZOFFSETTO:-0200
TZNAME:-02
DTSTART:20181104T030000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20180204T220000
DTEND;TZID=America/Sao_Paulo:20180205T025900
DTSTAMP:20260407T112140
CREATED:20180118T215257Z
LAST-MODIFIED:20180118T215257Z
UID:99995001-1517781600-1517799540@budmaps.com.br
SUMMARY:Event Name: Psychedelic Possibilities - Austin
DESCRIPTION:You are invited to a benefit dinner to heal trauma through MDMA therapy in Austin\, Texas\, on Sunday\, February 4\, 2018. \nJoin MAPS in creating a post-prohibition world\, where psychedelics can be used for therapy\, to inspire creativity\, to promote environmental stewardship\, to help solve global conflicts\, and to accomplish personal or spiritual growth. \nReserve your seats today to network among the company of like-minded individuals\, enjoy dinner and wine\, and show your support for psychedelic research by donating to MAPS’ mission. Meet movers and shakers in the psychedelic research community\, including MAPS staff\, scientists\, and celebrities who support our work.  \nPurchase tickets: maps.org/austin2018 \nMAPS Founder and Executive Director\, Rick Doblin\, Ph.D.\, will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines\, as valuable tools for inspiring creativity\, for personal and spiritual growth\, and for catalyzing resolutions to global and social conflicts. \nLeading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).  \n— \nBreakthrough Therapy Designation: \nPreliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies\, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation\, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials\, the final phase of research\, as efficiently as possible. \nPhase 3 trials require more clinical sites\, more therapists\, more patients\, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment\, which would radically shift policy and public perception surrounding psychedelics. \n— \nHealing Trauma: \nThere is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies\, we can work together toward healing millions of people suffering from PTSD. \nWe can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. \n— \nSpeakers: \nMAPS Founder and Executive Director\, Rick Doblin\, Ph.D.\, will host an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines\, as valuable tools for inspiring creativity\, for personal and spiritual growth\, and for catalyzing resolutions to global and social conflicts. His professional goal is to become a legally licensed psychedelic therapist. \nAubrey Marcus\, Founder and CEO\, ONNIT\, created ONNIT as a lifestyle brand based on a holistic health philosophy he calls Total Human Optimization. Since its founding\, Onnit has become an Inc. 500 company and industry leader with over 250 products ranging from peak performance supplements to foods\, fitness equipment\, and apparel. Aubrey currently hosts The Aubrey Marcus Podcast\, a destination for conversations with the brightest minds in athletics\, business\, science\, and philosophy with over 10MM downloads on iTunes. A sought-after public speaker and multi-platform media expert\, Aubrey regularly provides commentary to outlets like Entrepreneur\, Forbes\, Fusion\, The Doctors\, Dr. Oz\, and The Joe Rogan Experience. \nAlli Feduccia\, Ph.D.\, Clinical Data Scientist\, received a bachelor’s degree in Biological Psychology in 2009 from Louisiana State University. After earning a Ph.D. in Neuropharmacology from the University of Texas at Austin by utilizing rodent models to study the effects of MDMA on behavior and neurochemical release\, she held a postdoctoral research position in the Preclinical Development Group at Ernest Gallo Clinic and Research Center at the University of California San Francisco where her experiments aimed to discover novel treatment strategies for alcohol dependence by elucidating the mechanisms of action of medications used to treat substance use disorders. At MAPS PBC\, Alli is currently serving as the Clinical Data Scientist\, performing various tasks to ensure clinical data is analyzed and communicated in the highest quality for regulatory documents\, scientific publications\, and public presentations. She also makes online e-learning modules and creates content for a web-based learning management system to host training and educational material for site and therapy teams\, Zendo Project\, and other public educational outreach. Alli is passionate about starting a MAPS-sponsored trial of ayahuasca for treatment of alcohol use disorders and is currently applying her translational perspective to the development of a new protocol. \n— \nPurchase tickets: maps.org/austin2018 \nSpecial thanks to our hosts\, Aubrey Marcus and Whitney Miller\, and to our host committee (in formation): Jade Netanya Ullmann\, Robert Barnhart\, Roland Wiederaenders\, and Jason Havey. \nQuestions? Contact events@maps.org \n— \nAbout MAPS: \nThe Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical\, legal\, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986\, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD. \nLearn about our research and other events at maps.org
URL:https://budmaps.com.br/evento/event-name-psychedelic-possibilities-austin/
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_573579789654569.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20180128T000000
DTEND;TZID=America/Sao_Paulo:20180128T045900
DTSTAMP:20260407T112140
CREATED:20180105T225257Z
LAST-MODIFIED:20180105T225257Z
UID:99994972-1517097600-1517115540@budmaps.com.br
SUMMARY:Exploring Psychedelic Medicine - Fort Collins
DESCRIPTION:You are invited a launch party and benefit for MDMA-assisted psychotherapy research in Fort Collins\, Colorado\, on Saturday\, January 27\, 2018.  \nCelebrate the launch of our new research site at the Wholeness Center in Fort Collins\, where MDMA-assisted psychotherapy will be investigated as a treatment for posttraumatic stress disorder (PTSD) in a Phase 3 clinical trial. \nReserve your tickets today to network with like-minded people\, meet movers and shakers in the psychedelic research community\, enjoy light refreshments\, and contribute to this vital and promising movement. \nPurchase tickets: maps.org/fortcollins2018 \nMAPS Founder and Executive Director\, Rick Doblin\, Ph.D.\, will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines\, as valuable tools for inspiring creativity\, for personal and spiritual growth\, and for catalyzing resolutions to global and social conflicts. \nLeading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).  \n— \nBreakthrough Therapy Designation: \nPreliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies\, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation\, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials\, the final phase of research\, as efficiently as possible. \nPhase 3 trials require more clinical sites\, more therapists\, more patients\, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment\, which would radically shift policy and public perception surrounding psychedelics. \n— \nHealing Trauma: \nThere is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies\, we can work together toward healing millions of people suffering from PTSD. \nWe can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. \n— \nSpeakers: \nMAPS Founder and Executive Director Rick Doblin\, Ph.D.\, has a professional goal to help develop legal contexts for the beneficial uses of psychedelics and marijuana\, primarily as prescription medicines but also for personal growth for otherwise healthy people\, and eventually to become a legally licensed psychedelic therapist. \nDr. Scott Shannon\, a holistic physician\, psychiatrist\, acupuncturist\, and teacher\, will serve as the Principal Investigator Fort Collins PI at his clinic\, Wholeness Center\, which provides cross-disciplinary evaluation and care for mental health concerns. In 2001\, Dr. Shannon published the first textbook on holistic psychiatry and continues to be published widely. He shares his knowledge as an Assistant Clinical Professor at the University of Colorado and through Psychiatry MasterClass\, a program he was central in creating that provides professionals with in-depth education in integrative mental health. \nHania Withem was a participant in MAPS’ Phase 2 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder. Hania currently lives and works in Fort Collins\, Colorado. \nPurchase tickets: maps.org/fortcollins2018���\n— \nQuestions? Contact events@maps.org \nSpecial thanks to our host committee (in formation): Jade Netanya Ullmann. \n— \nAbout MAPS: \nThe Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical\, legal\, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986\, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD. \n�Learn about our research and other events at maps.org
URL:https://budmaps.com.br/evento/exploring-psychedelic-medicine-fort-collins/
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_1865183693722268.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20180126T000000
DTEND;TZID=America/Sao_Paulo:20180126T045900
DTSTAMP:20260407T112140
CREATED:20180105T215505Z
LAST-MODIFIED:20180105T215505Z
UID:99994970-1516924800-1516942740@budmaps.com.br
SUMMARY:Legalizing Psychedelic Medicine - Boulder
DESCRIPTION:You are invited to a benefit dinner to heal trauma through MDMA therapy in Boulder\, Colorado\, on Thursday\, January 25\, 2018. \nCelebrate the launch of our new research site in Boulder\, Colorado\, where MDMA-assisted psychotherapy will be investigated as a treatment for posttraumatic stress disorder (PTSD) in a Phase 3 clinical trial. \nReserve your seat today to join the company of like-minded individuals\, enjoy a 3-course meal\, and contribute to this vital and promising movement. \nPurchase tickets: maps.org/boulder2018 \nMAPS Founder and Executive Director\, Rick Doblin\, Ph.D.\, will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines\, as valuable tools for inspiring creativity\, for personal and spiritual growth\, and for catalyzing resolutions to global and social conflicts. \nLeading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).  \n— \nBreakthrough Therapy Designation: \nPreliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies\, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation\, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials\, the final phase of research\, as efficiently as possible. \nPhase 3 trials require more clinical sites\, more therapists\, more patients\, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment\, which would radically shift policy and public perception surrounding psychedelics. \n— \nHealing Trauma: \nThere is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies\, we can work together toward healing millions of people suffering from PTSD. \nWe can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. \n— \nSpeakers: \nMAPS Founder and Executive Director Rick Doblin\, Ph.D.\, has a professional goal to help develop legal contexts for the beneficial uses of psychedelics and marijuana\, primarily as prescription medicines but also for personal growth for otherwise healthy people\, and eventually to become a legally licensed psychedelic therapist. \nMarcela Ot’alora\, M.A.\, L.P.C.\, is a psychotherapist and an artist working in Boulder\, Colorado. Marcela worked as a co-therapist in MAPS’ first government-approved MDMA-assisted psychotherapy study in Madrid\, Spain\, served as the Principal Investigator for MAPS’ Phase 2 trial of MDMA-assisted psychotherapy study in Boulder\, Colorado\, and currently in the MDMA Therapist Training Study. Additionally\, she is a trainer for therapists working on MAPS’ upcoming Phase 3 studies for MDMA-assisted psychotherapy. \nBruce Poulter\, R.N.\, M.P.H.\, has been interested and worked much of his career with people in altered states. He has worked extensively with people in chronic pain and was an intimate observer of the first government-approved MDMA-assisted psychotherapy study in Madrid\, Spain\, in 1999. He has offered harm reduction services through Zendo Project\, was an investigator in the MAPS-sponsored Phase 2 MDMA/PTSD trial. and is currently an investigator in the MDMA Therapist Training Study. He ran for the U.S. Senate in 2002.  \nSara Gael\, M.A.\, received her Master’s degree in Transpersonal Counseling Psychology at Naropa University. She began working with MAPS in 2012\, coordinating psychedelic harm reduction services at festivals and events worldwide with the Zendo Project. Sara was an Intern Therapist for the recently-completed MAPS-sponsored Phase 2 clinical trial of MDMA-assisted psychotherapy for PTSD in Boulder\, CO. She maintains a private practice as a psychotherapist specializing in trauma and non-ordinary states of consciousness. \n— \nPurchase tickets: maps.org/boulder2018 \nSpecial thanks to members of our host committee (in formation): Sean Abraham and Jade Netanya Ullmann. \nQuestions? Contact events@maps.org \nA portion of ticket prices may be tax-deductible in the US. The fair market value of each ticket is $80. \n— \nAbout MAPS: \nThe Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical\, legal\, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986\, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD. \n�Learn about our research and other events at maps.org
URL:https://budmaps.com.br/evento/legalizing-psychedelic-medicine-boulder/
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_909858419175097.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20171013T200000
DTEND;TZID=America/Sao_Paulo:20171014T005900
DTSTAMP:20260407T112140
CREATED:20170915T185627Z
LAST-MODIFIED:20170915T185627Z
UID:99994281-1507924800-1507942740@budmaps.com.br
SUMMARY:Legalizing Psychedelic Medicine
DESCRIPTION:You are invited to an evening soirée in Atlanta. \nJoin the company of like-minded individuals\, share your perspective among other trailblazers\, and show your support for the legalization of psychedelic medicine. \nSpeakers: \nRick Doblin\, Ph.D.\, is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana\, primarily as prescription medicines but also for personal growth for otherwise healthy people\, and eventually to become a legally licensed psychedelic therapist. \nPsychologist Barbara Rothbaum\, Ph.D.\, is a leading PTSD researcher and currently serves as Principal Investigator of the ongoing MAPS-sponsored Phase 1 study on the effect of MDMA on startle testing in healthy volunteers\, taking place at Emory University in Atlanta\, Georgia. \nMAPS Founder and Executive Director\, Rick Doblin\, Ph.D.\, will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines\, as valuable tools for inspiring creativity\, for personal and spiritual growth\, and for catalyzing resolutions to global and social conflicts. \nLeading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).  \nBreakthrough Therapy Designation \nPreliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies\, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation\, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials\, the final phase of research\, as efficiently as possible. \nPhase 3 trials require more clinical sites\, more therapists\, more patients\, and more support.  This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment\, which would radically shift policy and public perception surrounding psychedelics. \nHealing Trauma \nThere is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies\, we can work together toward healing millions of people suffering from PTSD. \nWe can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. \nSpecial thanks to our host\, Barbara Meyers\, and our host committee member\, Marsha Rosenbaum. \nThis event coincides with the International Drug Policy Reform Conference in Atlanta\, Georgia\, taking place from October 11-14\, 2017. \nmaps.org/atlanta2017 \nFor more information\, contact the MAPS office at (831) 429-6362 or events@maps.org. \nLearn about our research and other events at maps.org
URL:https://budmaps.com.br/evento/legalizing-psychedelic-medicine-2/
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_131669490792047.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20171007T230000
DTEND;TZID=America/Sao_Paulo:20171008T035900
DTSTAMP:20260407T112140
CREATED:20170915T175757Z
LAST-MODIFIED:20170915T175757Z
UID:99994279-1507417200-1507435140@budmaps.com.br
SUMMARY:Legalizing Psychedelic Medicine
DESCRIPTION:You are invited to an evening soirée in Soho\, New York.  \nJoin the company of like-minded individuals\, share your perspective among other trailblazers\, enjoy a psychedelic comedy performance\, and show your support for the legalization of psychedelic medicine. \nSaturday\, October 7\, 2017\nDoors open at 7:00 P.M.\nFood served at 7:30 P.M.\nProgram begins at 9:00 P.M. \nSpeakers: \nMAPS Founder and Executive Director\, Rick Doblin\, Ph.D.\, will host an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines\, as valuable tools for inspiring creativity\, for personal and spiritual growth\, and for catalyzing resolutions to global and social conflicts. \nAuthor Rachel Hope overcame treatment-resistant PTSD after participating in MAPS’ Phase 2 clinical research. Rachel is now a public advocate for the legalization of this potentially life-saving therapy. \nShannon Clare Carlin\, M.A.\, is investigating MDMA-assisted psychotherapy for PTSD as a co-therapist at the Phase 3 study site in Los Angeles\, California. Shannon previously treated Phase 2 study participants for anxiety associated with life-threatening illness. Shannon serves as Therapy Training Program Manager\, and oversees education for therapists. \nComedian Adam Strauss’ work has been called many things\, mostly adjectives. The New York Times said The Mushroom Cure\, Adam’s true account of his attempt to treat his severe OCD with psychedelics\, “mines a great deal of laughter from disabling pain.” Time Out New York called it “riveting… a true-life tour de force” and named it a Critics’ Pick. \nBreakthrough Therapy Designation \nPreliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies\, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation\, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials\, the final phase of research\, as efficiently as possible. \nPhase 3 trials require more clinical sites\, more therapists\, more patients\, and more support.  This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment\, which would radically shift policy and public perception surrounding psychedelics. \nHealing Trauma \nTogether\, we can work to heal millions of people suffering from PTSD by supporting groundbreaking research into psychedelic therapies. This research is essential to obtaining government approval of MDMA-assisted psychotherapy as a legal treatment\, which would radically shift policy and public perception surrounding psychedelics. There is a need unmet by modern psychiatry and psychotherapy that psychedelic-assisted therapies can fill. \nWe can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs. The first $20\,000 donated on-site will be matched 2:1 by generous donors Laura and Ed Littlefield who pledged $40\,000. \nSpecial thanks to our hosts\, Giancarlo and Stephanie Canavesio\, and to host committee members Susan Brody\, Sheila Burgel\, Sir Ivan\, Joshua Mailman and Monica Winsor\, John McCormick\, Stefanie Frank\, Rodrigo Nino\, Daniel Pinchbeck\, Carey and Claudia Turnbull. Additional members to be announced. \nThis event coincides with the Horizons 2017: Perspectives on Psychedelics conference taking place in New York\, New York\, from October 6-8\, 2017. \nmaps.org/nyc2017 \nFor more information\, contact the MAPS office at (831) 429-6362 or events@maps.org. \nLearn about our research and other events at maps.org
URL:https://budmaps.com.br/evento/legalizing-psychedelic-medicine/
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_353136551795571.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20170424T000000
DTEND;TZID=America/Sao_Paulo:20170424T060000
DTSTAMP:20260407T112140
CREATED:20170405T010205Z
LAST-MODIFIED:20170405T010205Z
UID:99993871-1492992000-1493013600@budmaps.com.br
SUMMARY:Integration at Psychedelic Science 2017
DESCRIPTION:Decompress from Psychedelic Science\nand come shake your molecules on the dance floor! \n#integration \nJoin us for good music\, psychedelic art\, and Rick Doblin\, MAPS Founder and Executive Director\, who will share some brief reflections on Psychedelic Science. \nFeaturing:\nDrumspyder\nDJ Soular\nLiquid Love Drops \nWear your extraordinary attire and let’s party! \nA PARTY TO BENEFIT MAPS` POLICY & ADVOCACY TEAM.
URL:https://budmaps.com.br/evento/integration-at-psychedelic-science-2017/
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_1831153707148132.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Sao_Paulo:20170419T130000
DTEND;TZID=America/Sao_Paulo:20170424T220000
DTSTAMP:20260407T112140
CREATED:20170403T020026Z
LAST-MODIFIED:20170403T020026Z
UID:99993836-1492606800-1493071200@budmaps.com.br
SUMMARY:Psychedelic Science 2017
DESCRIPTION:Tickets are on sale for Psychedelic Science 2017\, taking place from April 19-24\, 2017\, in Oakland\, Calif.  \nAt Psychedelic Science 2017\, the international scientific community will come together at the Oakland Marriott City Center in Oakland\, Calif.\, to share and discover new research into the benefits and risks of MDMA\, LSD\, psilocybin\, ayahuasca\, ketamine\, ibogaine\, medical marijuana\, and more. \nPlease join us for this historic six-day global gathering\, featuring three days of conference presentations and three days of workshops\, a Sunset Cruise on the San Francisco Bay\, the world’s first Psychedelic Comedy Banquet\, and much more. \nPsychedelic Science 2017 is presented by the Multidisciplinary Association for Psychedelic Studies (MAPS) and The Beckley Foundation. \nFor more information visit: psychedelicscience.org
URL:https://budmaps.com.br/evento/psychedelic-science-2017/
LOCATION:Oakland Marriott City Center\, 1001 Broadway\, Oakland\, CA\, 94607\, United States
ATTACH;FMTTYPE=image/jpeg:https://budmaps.com.br/wp-content/uploads/facebook_event_1156875991047651.jpg
GEO:37.8021736;-122.2729171
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Oakland Marriott City Center 1001 Broadway Oakland CA 94607 United States;X-APPLE-RADIUS=500;X-TITLE=1001 Broadway:geo:-122.2729171,37.8021736
END:VEVENT
END:VCALENDAR